NCT03944369 - VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 27, 2019

Primary Completion Date

June 16, 2020

Study Completion Date

June 16, 2020

Conditions

Vancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized Subjects

Interventions

OTHER

KB109

KB109 is a novel glycan

OTHER

No intervention

Trial Locations (8)

11794

Stony Brook University, Stony Brook

15213

University of Pittsburgh Medical Center, Pittsburgh

28207

Atrium Health's Carolinas Medical Center, Charlotte

30322

Emory University, Atlanta

48075

Newland Immunology Center of Excellence; Providence Hospital, Southfield

77030

The University of Texas Health Science Center at Houston, Houston

90509

Harbor UCLA Medical Center, Torrance

301912

Augusta Universtiy, Augusta